O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+12.32%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.22B
AUM Growth
+$5.22B
(+97,106%)
Cap. Flow
+$35.6M
Cap. Flow
% of AUM
0.68%
Top 10 Holdings %
Top 10 Hldgs %
34.68%
Holding
137
New
7
Increased
25
Reduced
21
Closed
21
Top Buys
| 1 |
UnitedHealth
UNH
|
$60.1M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$46.3M |
| 3 |
Tenet Healthcare
THC
|
$28.2M |
| 4 |
Vaxcyte
PCVX
|
$27.1M |
| 5 |
Evolent Health
EVH
|
$23.3M |
Top Sells
| 1 |
argenx
ARGX
|
$96M |
| 2 |
Disc Medicine
IRON
|
$72.9M |
| 3 |
Pfizer
PFE
|
$61.8M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$29.4M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$29.3M |
Sector Composition
| 1 | Healthcare | 98.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.5% | 2,718,735 | – | – |
|
|
2
UnitedHealth
UNH
$281B
| $202M | 3.86% | 380,500 +113,300 | +42% | +$60.1M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $186M | 3.56% | 2,584,900 | – | – |
|
4
Boston Scientific
BSX
$156B
| $180M | 3.45% | 3,898,200 | – | – |
|
5
Humana
HUM
$36.5B
| $179M | 3.42% | 348,700 | – | – |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $167M | 3.2% | 1,615,210 -102,100 | -6% | -$10.6M |
|
7
Intuitive Surgical
ISRG
$170B
| $165M | 3.15% | 620,500 +47,800 | +8% | +$12.7M |
|
|
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
| $137M | 2.61% | 5,250,000 -275,926 | -5% | -$7.18M |
|
9
Edgewise Therapeutics
EWTX
$1.51B
| $130M | 2.49% | 14,567,176 | – | – |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $126M | 2.41% | 972,300 +53,800 | +6% | +$6.97M |
|
|
VRNA
11
Verona Pharma
VRNA
$9.16B
| $119M | 2.29% | 4,572,289 -1,122,552 | -20% | -$29.3M |
|
12
Stryker
SYK
$150B
| $118M | 2.25% | 481,000 +57,900 | +14% | +$14.2M |
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $117M | 2.25% | 913,812 +151,212 | +20% | +$19.4M |
|
14
Compass Therapeutics
CMPX
$483M
| $112M | 2.15% | 22,362,850 +402,000 | +2% | +$2.02M |
|
15
Thermo Fisher Scientific
TMO
$186B
| $111M | 2.13% | 202,200 | – | – |
|
|
THRX
16
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $85.8M | 1.64% | 17,233,668 +192,000 | +1% | +$956K |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $82.1M | 1.57% | 687,700 -208,845 | -23% | -$24.9M |
|
18
Keros Therapeutics
KROS
$618M
| $80.6M | 1.54% | 1,679,417 | – | – |
|
|
19
Evolent Health
EVH
$1.12B
| $79.3M | 1.52% | 2,824,832 +830,115 | +42% | +$23.3M |
|
|
20
Vertex Pharmaceuticals
VRTX
$100B
| $78.4M | 1.5% | 271,500 -101,700 | -27% | -$29.4M |
|
21
Natera
NTRA
$23.1B
| $78.2M | 1.5% | 1,946,353 +441,200 | +29% | +$17.7M |
|
22
Terns Pharmaceuticals
TERN
$609M
| $77.6M | 1.48% | 7,619,135 +137,931 | +2% | +$1.4M |
|
|
23
Ionis Pharmaceuticals
IONS
$6.79B
| $75.3M | 1.44% | 1,993,600 +1,224,700 | +159% | +$46.3M |
|
24
ARS Pharmaceuticals
SPRY
$1.15B
| $74.6M | 1.43% | 8,740,887 | – | – |
|
25
Biogen
BIIB
$19.4B
| $71.5M | 1.37% | 258,200 +33,600 | +15% | +$9.3M |
|